洛拉提尼布血度与不良事件之间的关联以及剂量修改的临床影响
Yukiko Igawa1, Tatsuya Yoshida2, Reiko Makihara3
1Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
洛拉提尼布的剂量修改通过降低血度,有效地管理诸如高脂血症和中枢神经系统疾病等不良事件. 这一策略允许继续治疗ALK重组的非小细胞肺癌患者.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 洛拉提尼布是一种第三代ALK抑制剂,用于高级ALK重组NSCLC.
- 洛拉提尼布可以引起不同的不良事件 (AE),包括高脂血症和中枢神经系统疾病.
- 通过剂量调整来最佳管理洛拉提尼布诱导的副作用需要进一步的研究.
研究的目的:
- 调查洛拉提尼布暴露与AEs之间的关联.
- 为了确定剂量修改是否可以达到血中罗拉提尼布的最佳度.
- 评估剂量修改对洛拉提尼布诱导的副作用的影响.
主要方法:
- 55名患有晚期ALK重组NSCLC的患者进行了回顾性审查,这些患者接受了洛拉提尼布治疗.
- 使用高性能液体染色学-并联质谱法评估血清洛拉提尼布度.
- 使用常用术语标准对不良事件的AE的评估版本5.0.0.
主要成果:
- 45%的患者经历了3级以上的副作用,包括高脂血症 (31%) 和中枢神经系统疾病 (13%).
- 与没有 (462 ng/mL与177 ng/mL) 相比,Lorlatinib血清度在3级≥3级AE患者中显著更高.
- 剂量调整有效降低了洛拉提尼布的血清度,并促进了治疗的继续.
结论:
- 洛拉提尼布的剂量修改与AEs的成功管理有关.
- 在剂量修改后观察到洛拉提尼布的血清度降低.
- 这一策略有助于在持续的洛拉提尼布的管理,同时管理AE.
更多相关视频
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
相关概念视频
Time Course of Drug Effect
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
